Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06816927 · ClinicalTrials.gov registry record · Phase 2
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
A Phase 2 study of Newly Diagnosed Glioblastoma, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT06816927 is a Phase 2 study of Newly Diagnosed Glioblastoma that is actively recruiting participants, run by Duke University. The registered enrollment target is 92 participants, above the 66-participant average among 4 other Newly Diagnosed Glioblastoma trials with a reported enrollment target (39% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06816927, a Phase 2 study of Newly Diagnosed Glioblastoma, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
GIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate the feasibility, safety and tolerability, and establish the biological activity of nivolumab with or without relatlimab in patients with isocitrate dehydrogenase (IDH) wildtype newly diagnosed glioblastoma (ndGBM).
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Relatlimab
- RADIATION Radiation Therapy
- DRUG TMZ
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2025-11-28 |
| Est. Completion | 2031-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06816927
The ClinicalTrials.gov registry entry for NCT06816927 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 66-participant average among 4 other Newly Diagnosed Glioblastoma trials with a reported enrollment target (39% higher). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Newly Diagnosed Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT06816927 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06816927 about?
NCT06816927 is a clinical study titled "Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab". GIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate the feasibility, safety and tolerability, and establish the biological activity of nivolumab with or without relatlimab in patients with isocit...
What is the current status of trial NCT06816927?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2025-11-28. Estimated completion is 2031-06-01.
What conditions does trial NCT06816927 study?
This clinical trial studies the following conditions: Newly Diagnosed Glioblastoma.
What interventions are being tested in trial NCT06816927?
The interventions under investigation include: Nivolumab (DRUG), Relatlimab (DRUG), Radiation Therapy (RADIATION), TMZ (DRUG).
Who is sponsoring clinical trial NCT06816927?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06816927 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Newly Diagnosed Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma
RECRUITING · Early Phase 1
-
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.